Discontinuous conductive filler polymer-matrix composites for electromagnetic shielding

Information

  • Patent Grant
  • 10398893
  • Patent Number
    10,398,893
  • Date Filed
    Wednesday, May 20, 2015
    9 years ago
  • Date Issued
    Tuesday, September 3, 2019
    5 years ago
Abstract
A medical electrical lead having a conductor assembly covered by an insulating layer, and a shield covering positioned adjacent or proximate to at least a portion of the insulating layer in order to shield the conductor assembly from one or more electromagnetic fields. The shield covering is formed of a polymer-matrix composite. The polymer-matrix composite includes a polymeric resin having discontinuous conductive fillers provided therein. The discontinuous conductive fillers include one or more of nano-sized metal structures and nano-sized non-metallic conductive structures. The nano-sized non-metallic conductive structures can have a coating formed of one or more metals. The nano-sized non-metallic conductive structures can be formed of carbon. In turn, the nano-sized non-metallic conductive structures can include one or more of carbon nanofibers, carbon filaments, carbon nanotubes, and carbon nanoflakes.
Description
FIELD

The present invention relates generally to medical devices, and, more particularly, to reducing the effects of electromagnetic radiation on such medical devices.


BACKGROUND

Since their earliest inception, implantable medical devices (IMDs) have continually been advanced in significant ways. Today, IMDs include therapeutic and diagnostic devices, such as pacemakers, cardioverter/defibrillators, hemodynamic monitors, neurostimulators, and drug administering devices, as well as other devices for alleviating the adverse effects of various health ailments.


As is known, modern electrical therapeutic and diagnostic devices for the heart and other areas of the body generally include an electrical connection between the device and the body. This connection is usually provided by at least one medical electrical lead. For example, a neurostimulator delivers mild electrical impulses to neural tissue using one or more electrical leads. In turn, such neurostimulation often results in effective pain relief and a reduction in the use of pain medications and/or repeat surgeries. Each electrical lead used with such devices typically takes the form of a long, generally straight, flexible, insulated conductor. At its proximal end, the lead is typically connected to a connector of the device, which also may be implanted within the patient's body. Generally, one or more electrodes are located at or near the distal end of the lead and are attached to, or otherwise come in contact with, the body. Such devices may be controlled by a physician or a patient through the use of an external programmer.


It is well known that, if not shielded sufficiently, the implanted leads of medical devices can be adversely affected when a patient is exposed to alternating electromagnetic fields. Alternating electromagnetic fields can generally stem from any of a number of radio-frequency radiation sources, e.g., magnetic resonance imaging (MRI) systems as described below. As such, if an implanted medical lead is not sufficiently shielded, electromagnetic fields can induce an electric current within a conductor of the lead. In turn, such an implanted electrical lead would act as an antenna, resulting in an electrical current that flows from the electrode of the lead and through body tissue. Because the tissue area associated with electrode contact may be very small, the current densities may be high, which can result in tissue heating that may cause damage.


There can be other limitations associated with exposing implanted leads of medical devices to electromagnetic fields and/or radio-frequency energy if the leads are not sufficiently shielded therefrom. As is known, a sudden burst of radio-frequency energy can cause an electric pulse within the lead. The medical device, as should be appreciated, can sense the imposed voltage on the lead, and in turn, may cause the device to respond inappropriately, resulting in the wrong therapy being administered to the patient at that time or in the future. For example, with respect to cardiac IMDs, inappropriate therapy modification may be one response of the IMD, which can involve changing the rate or thresholds associated with pacing pulses.


As is known, magnetic resonance imaging (MRI) is an anatomical imaging tool which utilizes non-ionizing radiation (i.e., no x-rays or gamma rays) and provides a non-invasive method for the examination of internal structure and function. For example, MRI permits the study of the overall function of the heart in three dimensions significantly better than any other imaging method. Furthermore, MRI scanning is widely used in the diagnosis of diseases and injuries to the head. Magnetic resonance spectroscopic imaging (MRSI) systems are also known and are herein intended to be included within the terminology “MRI” systems or scanners. These MRI systems can be used to give valuable diagnostic information, but also subject the patient to significant alternating electromagnetic fields and/or radio-frequency energy, which may result in one or more of the undesirable effects described above with respect to IMDs or medical devices using implanted leads.


A variety of different coverings have been used for implantable leads of medical devices to overcome the above limitations. Some coverings have involved metal or metal alloy wire being braided around the lead, thereby forming a shield having a large conductive surface area. Other coverings have involved the use of polymer-matrix composites. Such composite coverings, as opposed to metal wire coverings, are attractive due to their moldability. In addition, the composite coverings are more favorable because metal wire coverings can be prone to damage by scratching, abrasion, or wear.


Polymer-matrix composite coverings are conductive due to the presence therein of electrically conducting fillers, which can be discontinuous (e.g., such as particles or short fibers) or continuous (e.g., such as continuous fibers). As is known, even though they lack the continuity provided by continuous fillers, discontinuous fillers can just as well be used for electromagnetic shielding. Moreover, discontinuous fillers are suitable for composite fabrication by extrusion or injection molding and, if the discontinuous filler is fine enough in size, even by ink-jet printing or screen printing. Due to the lower cost and greater versatility of composite fabrication for discontinuous fillers compared to continuous fillers, discontinuous fillers have been widely used in making electrically conducting composites, especially those for electromagnetic shielding.


While polymer-matrix composites having discontinuous fillers have been used as lead coverings to reduce the effects of electromagnetic radiation, they have been found to present certain limitations, e.g., with respect to their overall shielding effectiveness. What is needed is apparatus used to reduce the potential adverse effects to medical devices, and in particular, to implantable electrical leads of the devices, when subjected to electromagnetic radiation, while further overcoming one or more of the limitations facing the discontinuous filler polymer-matrix composite lead coverings marketed to date.


BRIEF SUMMARY OF THE INVENTION

Embodiments of the invention relate to a medical electrical lead having a conductor assembly covered by an insulating layer, and a shield covering positioned adjacent or proximate to at least a portion of the insulating layer in order to shield the conductor assembly from one or more electromagnetic fields. The shield covering is formed of a polymer-matrix composite. The polymer-matrix composite includes a polymeric resin having discontinuous conductive fillers provided therein. The discontinuous conductive fillers include one or more of nano-sized metal structures and nano-sized non-metallic conductive structures. The nano-sized non-metallic conductive structures can have a coating formed of one or more metals. The nano-sized non-metallic conductive structures can be formed of carbon. In turn, the nano-sized non-metallic conductive structures can include one or more of carbon nanofibers, carbon filaments, carbon nanotubes, and carbon nanoflakes.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an exemplary IMD as provided in a patient in accordance with certain embodiments of the invention.



FIG. 2 is a perspective view of another exemplary IMD as provided in a patient in accordance with certain embodiments of the invention.



FIG. 3 is a perspective view of a further exemplary IMD as provided in a patient in accordance with certain embodiments of the invention.



FIG. 4 is a plot generally showing skin depth for carbon and metals at high frequencies of electromagnetic fields.



FIG. 5 is a plot generally showing conductivity of carbon nanofibers and carbon nanotubes at varying weight percentages of polymer-matrix composites.



FIG. 6 is a plot generally showing conductivity of carbon nanofibers at varying volume percentages of polymer-matrix composites.



FIG. 7 is a plot generally showing electromagnetic shielding effectiveness of carbon micro fiber, carbon filament, and nickel filament.



FIG. 8 is a perspective view of a partial implantable lead/extension having a shield covering in accordance with certain embodiments of the invention.



FIG. 9 is a cross-sectional view of an implantable lead/extension having a plurality of shield coverings, including those of FIG. 8, in accordance with certain embodiments of the invention.



FIG. 10 is a cross-sectional view of an implantable lead/extension having another plurality of shield coverings, including those of FIG. 8, in accordance with certain embodiments of the invention.



FIG. 11 is a cross-sectional view of an implantable lead/extension having a further plurality of shield coverings, including those of FIGS. 8, 9, and 10, in accordance with certain embodiments of the invention.



FIG. 12 is a cross-sectional view of an implantable lead/extension having another further plurality of shield coverings, including those FIG. 8, in accordance with certain embodiments of the invention.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The following detailed description should be read with reference to the drawings, in which like elements in different drawings are numbered identically. The drawings depict selected embodiments and are not intended to limit the scope of the invention. It will be understood that embodiments shown in the drawings and described below are merely for illustrative purposes, and are not intended to limit the scope of the invention as defined in the claims.


Embodiments of the invention relate to medical devices, and specifically relate to shield coverings for leads extending between the devices and the patient. Embodiments described and illustrated herein pertain to implantable medical devices (IMDs); however, the invention can extend to any lead-bearing medical device, whether implantable or not. Furthermore, while the embodiments provided herein relate to certain IMDs, it should be appreciated that such embodiments are exemplary in nature. As such, the invention is not limited to any particular IMD, but instead is applicable to any IMD, including therapeutic and diagnostic devices, such as pacemakers, cardioverter/defibrillators, hemodynamic monitors, neurostimulators, and drug administering devices, as well as other devices for alleviating the adverse effects of various health ailments.



FIG. 1 illustrates an exemplary IMD in accordance with certain embodiments of the invention. The IMD 10 shown is a typical spinal cord stimulation (SCS) system and includes a pulse generator such as a SCS neurostimulator 12, a lead extension 14 having a proximal end coupled to the neurostimulator 12, and a lead 16 having a proximal end coupled to a distal end of the extension 14 and having a distal end coupled to one or more electrodes 18. The neurostimulator 12 is typically placed in the abdomen of a patient 20, and the lead 18 is placed somewhere along the patient's spinal cord 22. While only shown with a single lead 18, it is to be appreciated that the IMD 10, in certain embodiments, can have a plurality of leads. Such a system may also include a physician programmer and a patient programmer (not shown).


The neurostimulator 12 may be considered to be an implantable pulse generator and capable of generating multiple pulses occurring either simultaneously or one pulse shifting in time with respect to the other, and having independently varying amplitudes and pulse widths. The neurostimulator 12 contains a power source and electronics for sending precise, electrical pulses to the spinal cord 22 to provide the desired treatment therapy. While the neurostimulator 12 typically provides electrical stimulation by way of pulses, other forms of stimulation may be used such as continuous electrical stimulation.


The lead 16 includes one or more insulated electrical conductors each coupled at their proximal end to a connector 24 and to the electrodes 18 (or contacts) at its distal end. As is known, some leads are designed to be inserted into a patient percutaneously and some are designed to be surgically implanted. In certain embodiments, the lead 16 may contain a paddle at its distant end for housing the electrodes 18. In alternate embodiments, the electrodes 20 may comprise one or more ring contacts at the distal end of the lead 16.


While the lead 16 is shown as being implanted in position to stimulate a specific site in the spinal cord 22, it could also be positioned along the peripheral nerve or adjacent neural tissue ganglia or may be positioned to stimulate muscle tissue. Furthermore, electrodes 18 (or contacts) may be epidural, intrathecal or placed into spinal cord 22 itself. Effective spinal cord stimulation may be achieved by any of these lead placements. While the lead connector at proximal end of the lead 16 may be coupled directly to the neurostimulator 12, the lead connector is typically coupled to the lead extension 14 as is shown in FIG. 1.



FIG. 2 illustrates another exemplary IMD in accordance with certain embodiments of the invention. The IMD 30 shown is a typical deep brain stimulation (DBS) system spinal cord stimulation (SCS) system and includes substantially the same components as does an SCS; that is, at least one neurostimulator, at least one extension, and at least one stimulation lead containing one or more electrodes. As can be seen, each neurostimulator 32a and 32b is implanted in the pectoral region of patient 34. Corresponding extensions 36a and 36b are deployed up through the patient's neck, and corresponding leads 38a and 38b are implanted in the patient's brain 40 as is shown at 42a and 42b. As can be seen, each of the leads 38 is connected to its respective extension 36 just above the ear on both sides of the patient 34.



FIG. 3 illustrates a further exemplary IMD in accordance with certain embodiments of the invention. The IMD 50 is a cardiac medical device, exemplarily shown as a pacemaker, and includes one or more leads 52 implanted in a patient 54. The leads 52 extend from the pacemaker can 56 and lead into the patient's heart 58 via a vein 60. Located generally near distal ends 62 of the leads 52 are one or more exposed conductive electrodes 64 that are attached to the heart tissue for sensing cardiac activity, delivering electrical pacing stimuli, and/or providing a cardioversion/defibrillation shock to the heart 58. The contact area between the electrodes 64 and the tissue of the heart 58 may be very small as compared, for example, to the contact area between the IMD 50 and the patient's body.


Implantable leads of IMDs similar to those described above in FIGS. 1-3, as well as implantable leads of other medical devices, have been equipped to reduce the effect from electromagnetic fields and/or radio-frequency energy, e.g., which can stem from MRI systems. To this end, the leads can be covered with polymer-matrix composites. Polymer-matrix composites, as used herein, include a polymeric resin having conductive fillers provided therein. As described above, the fillers can be discontinuous or continuous. As further described above, polymer-matrix composites having discontinuous fillers tend to be particularly attractive, as opposed to continuous filler composites, due to their lower cost and greater versatility of fabrication. Unfortunately, polymer-matrix lead coverings having discontinuous fillers have been found to present challenges, e.g., with respect to their overall shielding effectiveness.


One material that can be used when forming discontinuous fillers for use in polymer-matrix composites is carbon; however, the invention should not be limited to such. Instead, any other conductive material demonstrating similar advantageous properties, as described herein with respect to carbon, may be alternatively used. When provided in a discontinuous form, carbon can be presented in a wide variety of structures, including particulates, powders, fibers, filaments, flakes, and the like. In general, such structures are commercially available and practical to produce in sizes typically on the order of micrometers. For example, carbon filaments/fibers can be provided having outer diameters ranging in size from about 0.1 μm to about 12 μm. As should be appreciated, these diameter sizes are significantly reduced from the diameter sizes of commercially available metal wire (e.g., typically having minimum outer diameters of about 20 μm). As a result, such discontinuous carbon fillers are found to be less susceptible to the skin effect at high frequencies as compared to discontinuous metal wire fillers, as described below.


In general, when a static electrical field is applied to a conductor, the mobile charges therein, e.g., the electrons, are found to move and create a direct current (DC), which is uniformly distributed on the entire cross section of the conductor, resulting in a uniform current density. However, when an electromagnetic field is imposed on such a conductor, the mobile charges therein are found to oscillate back and forth with the same frequency as the impinging fields. The movement of these charges constitutes an alternating current (AC). Due to the attenuation of the electromagnetic waves in the conductor, the conductor's current density is greatest at the conductor's surface and declines exponentially as a function of depth. The decline in current density versus depth is known as the skin effect, and the skin depth is a measure of the distance over which the current falls from its value at the conductor's surface.



FIG. 4 is a plot illustrating skin effect for carbon and a number of metals, illustrating the relationship described above. Specifically, the plot shows skin depth (in μm) for carbon and a number of metal wires at high frequencies (in GHz) of electromagnetic fields. As illustrated, skin depth for the materials generally decreases as frequency increases (with respect to electromagnetic fields surrounding the materials). Thus, while metals are generally known to exhibit high conductivity, the cross-sectional area of these metals which is actually usable for such purposes is limited due to the skin effect.


As shown, carbon is also limited due to the skin effect, but to a lesser extent than the metals. However, as described above, carbon fiber can be made having a smaller diameter than metal wire. As a result, a larger cross-sectional area of the carbon fiber can be used for conductive purposes in comparison to conventionally available metal wire. Therefore, carbon fiber can be found to be more efficient than metal wire, in particular, when used as a shield in the presence of high frequency electromagnetic fields. For example, as demonstrated in FIG. 4, skin depth of conductive metals is typically less than 1 μm when the frequency of surrounding electromagnetic fields is about 64 MHz or higher. As such, discontinuous metal fillers, even having minimum diameters of about 20 μm, are not very effective shields because much of their cross-sectional area would carry very little current. In contrast, discontinuous carbon fibers, which can be provided having outer diameters of about 0.1 μm to about 12 μm can be much more effective in their use as shields because a higher percentage of their cross section can be used for carrying current, and in turn, conducting.


As is known, for a polymer-matrix composite, the electromagnetic radiation shielding effectiveness increases with increasing filler volume fraction in the composite. However, the maximum filler volume fraction is limited by the poor composite mechanical properties at high filler volume fractions resulting from the poor filler-matrix bonding. As described above, discontinuous carbon can generally be preferable to discontinuous metal wire because a higher percentage of the cross-sectional area of the carbon can be used for conductivity purposes, particularly in the presence of high frequency electromagnetic fields. Though, even with this increased efficiency, the usable cross-sectional area of the carbon is generally found to be less conductive than metal wire. However, because the carbon, e.g., carbon fiber, is smaller in diameter than metal wire, a greater quantity of such carbon can be utilized in the matrix material. In turn, the increased efficiency of the carbon (as described above with respect to skin depth) with the greater quantity of carbon in the matrix material enables the carbon to collectively exhibit enhanced conductivity throughout the composite. As such, using micro-sized carbon in polymer-matrix composites provides a more effective shield as a lead covering in the presence of electromagnetic fields as opposed to metal wire.


Further, when fillers are provided that are conductive yet smaller in size than their alternatives, as is the case in the above example comparing micro-sized carbon and metal wire, the matrix material of the composite can also be reduced while still maintaining the warranted volume fractions of the composite. As a result, a thinner lead covering can be provided that is more effective at shielding the electrical lead. Further, provided the micro-sized carbon and other alternative filler material are comparable in price, materials and process savings can be realized by using micro-sized carbon while still providing good mechanical properties for the composite.


While the above embodiment demonstrates higher electromagnetic radiation shielding effectiveness being achieved when using micro-sized carbon instead of metal wire as discontinuous fillers in polymer-matrix composites, even higher shielding effectiveness can be achieved in such composites. As described above, carbon structures can be made discontinuous so as to have sizes on the order of micrometers. However, carbon structures can also be further reduced in size on the order of nanometers. Examples of such carbon structures include nanofibers, filaments, nanotubes, and nanoflakes. Alternatively, certain metals can be formed into nano-sized structures, e.g., particles and/or flakes, which would also be more effective as fillers in comparison to discontinuous wire or micro-sized carbon structures. Such fillers can include but are not limited to Ag, Au, Cu, Co, Ni, Pt, Sn, Ta, Ti, Zn, or any alloys thereof.


Accordingly, in certain embodiments, a polymer-matrix composite is provided having discontinuous fillers, with the fillers including one or more of nano-sized non-metallic conductive structures and nano-sized metal structures. The use of the term “structures” herein with respect to “nano-sized non-metallic conductive structures” and “nano-sized metal structures” is meant to indicate “one or more different structures” in making up the fillers in each case. In certain embodiments, as described above, the nano-sized non-metallic conductive structures can be formed of carbon. In turn, in certain embodiments, the nano-sized non-metallic conductive structures can include one or more of carbon nanofibers, carbon filaments, carbon nanotubes, and carbon nanoflakes. For example, carbon nanofibers are widely available from a number of commercial sources, one being Pyrograf Products, Inc., an affiliate of Applied Sciences, Inc., located in Cedarville, Ohio. One such carbon nanofiber provided by Pyrograf Products, Inc. is the Pyrograf®-III, ranging in diameter from about 70 and about 200 nanometers. In many cases, carbon nanofiber is commercially available ranging in diameter from about 70 to about 500 nanometers. The nano-sized metal structures can be introduced to the composite using commercially available nano-sized metal particles or by means of in-situ reduction of desired metal ions injected into the matrix via chemical method, metal ion implantation method, or other suitable methods.


As should be appreciated, similar to that already described above in comparing discontinuous fillers of conventional carbon structures and metal wire, when nano-sized carbon and/or nano-sized metal are used instead of the conventional micro-sized carbon and/or metals in forming the fillers, the resulting composites would have enhanced electromagnetic shielding effectiveness. As such, discontinuous fillers formed of nano-sized carbon structures and/or nano-sized metal structures, because of their reduced size (as compared to conventional micro-sized carbon and/or metals of same volume fraction), would be less susceptible to skin effect at high frequencies. Further, because of their reduced size, the discontinuous fillers formed of nano-sized carbon structures and/or nano-sized metal structures can be provided in increased quantity in the matrix material compared to micro-sized carbon fiber structures and discontinuous metal wire.


In some cases, nano-sized carbon structures may be selected over nano-sized metal structures. One reason may be due to cost considerations. However, as should be appreciated, using nano-sized carbon structures in polymer-matrix composites can be costly as compared to using conventional micro-sized carbon structures. One way to address this is to select the least costly of the carbon nano-sized structures. As is known, carbon nanofibers and carbon nanoflakes are less expensive to produce than carbon nanotubes. For example, material cost to produce one pound of Pyrograf®-III carbon nanofibers is less than $50, while producing the same amount of single walled carbon nanotubes, e.g., from CarboLex, Inc., located in Lexington, Ky., is about $16,030. As such, in terms of cost considerations, carbon nanofiber is generally preferred over carbon nanotubes.


Further advantages in using carbon nanofiber are illustrated with respect to FIGS. 5 and 6. FIG. 5 is a plot illustrating electromagnetic shielding effect of carbon nanofibers and carbon nanotubes. Specifically, the plot shows bulk conductivity (in S/cm) for carbon nanofibers (from Pyrograf Products, Inc.) and single walled carbon nanotubes (from CarboLex, Inc.), given varying weight percentages of the carbon materials in polymer-matrix composites. As shown, the minimum requirement for electromagnetic shielding (about 1 S/cm) is initially met for carbon nanofibers when provided at about 10% weight of the composite, and then exceeded given greater weight percentages. In contrast, the minimum requirement for electromagnetic shielding is barely met by the carbon nanotubes, and only when the carbon nanotubes are provided at between about 25% and 30% weight of the composite. FIG. 6 is a plot illustrating conductivity (in S/cm) for carbon nanofibers, given varying volume percentages in polymer-matrix composites. As shown, the curve is similar to the one shown in FIG. 5 for carbon nanofibers, where the minimum requirement for electromagnetic shielding (about 1 S/cm) is initially met for the carbon nanofibers when provided at about 7% weight of the composite, and then exceeded given greater weight percentages. In summary, carbon nanofibers demonstrate significantly higher electromagnetic shielding effectiveness as compared to carbon nanotubes.


One challenge encountered to date in using nano-sized carbon structures as discontinuous fillers in polymer-matrix composites is their natural tendency to clump together. As such, effective dispersion of the nano-sized carbon structures throughout the matrix material can be difficult, which in turn, can compromise the shielding effectiveness of such composites. For example, if a quantity of carbon nanofibers is selected based on a uniform distribution throughout the matrix material, if the fibers clump, this uniform distribution would be difficult to achieve. In turn, the shielding effectiveness would likely not be uniformly dispersed through the composite, leaving some areas more susceptible to penetration by electromagnetic radiation.


It has been found through experimentation that this clumping phenomenon of nano-sized carbon structures can be overcome. Specifically, by providing a thin coating of metal on the nano-sized carbon structures prior to their disbursement in matrix material when forming polymer-matrix composites, one can offset the natural tendency of the nano-sized carbon structures to clump together. As a result, uniform shielding effectiveness for the composite can be achieved using nano-sized carbon structures, e.g., carbon nanofibers, which have a tendency to clump together. As such, in certain embodiments, carbon nanofibers, carbon filaments, carbon nanotubes, and carbon nanoflakes used as fillers can be provided with a metal coating. Such metal coating, in certain embodiments, can be provided so as to be no greater than about 1 μm. Metalization of carbon nanofibers, carbon filaments, carbon nanotubes, and carbon nanoflakes can be achieved via physical vapor deposition, chemical vapor deposition, auto-catalytic electroless deposition, or other metallization techniques known to the art. The metal coating can include but are not limited to Ag, Au, Cu, Co, Ni, Pt, Sn, Ta, Ti, Zn, alloys thereof, as well as any combination thereof.


It should be appreciated that such metal coating also enhances the conductivity, and thus, shielding effectiveness, of the carbon structures. For example, the metal coating can be made of nickel. FIG. 7 shows electromagnetic shielding effectiveness of carbon fiber, carbon filament, and nickel filament, each at commercially available diameter sizes. Of the three, the nickel filament demonstrates the highest electromagnetic shielding effectiveness, where the volume fraction of the nickel filament indicates that such composite can be processed, e.g., as tubing, to be used as a coating for discontinuous fillers in polymer-matrix composites.



FIG. 8 illustrates a perspective view of a partial implantable lead/extension having a shield covering in accordance with certain embodiments of the invention. As shown, the lead/extension 70 includes a conductor assembly having one of more conductors (not shown) covered by an insulating layer 72. As should be appreciated, the one or more conductors can be formed of any suitable metal having conductive properties, such as Cu, Al, Ag, alloys thereof or other alloys (e.g., superalloy MP35N), mixtures thereof, and the like. Further, as should be appreciated, each of the one or more conductors can be configured into one of a wide variety of shapes, e.g., generally straight, helically wound, etc. The insulating layer 72 is generally formed of silicone, a biocompatible polymer such as polyurethane, or any suitable biocompatible, non-conducting material known in the art.


As shown, the lead/extension 70 has a shield covering 74, which functions to shield electromagnetic radiation from the lead conductors. In certain embodiments, the shield covering 74 is provided as a polymer-matrix composite. As described herein, the polymer-matrix composite generally includes a polymeric resin 76 having conductive fillers provided therein. As shown, in certain embodiments, the conductive fillers are discontinuous conductive fillers. The discontinuous conductive fillers, in certain embodiments, can be nano-sized non-metallic conductive structures 78, nano-sized metal structures 80, or the combination of both (as exemplarily shown in FIG. 8). The distribution of the fillers can be uniformly distributed throughout the composite matrix (as illustrated in FIG. 8), or gradiently distributed with higher concentration at the surface of the shield tube (not shown in the Figure) so as to take advantage of both shield effect and mechanical properties of the polymer composite tube. The polymeric resin may be selected from any of a wide variety of thermoplastic resins and elastomers, blends of thermoplastic resins, and/or thermoset resins. Some nonlimiting examples of each of these resin types are provided in U.S. patent application Ser. No. 09/683,069, entitled “Conductive Plastic Compositions and Method of Manufacture Thereof”, incorporated herein in relevant part.


As described above, in certain embodiments, the nano-sized non-metallic conductive structures 78 can be formed of carbon. The carbon structures, in certain embodiments, can include one or more of carbon nanofibers, carbon filaments, carbon nanotubes, and carbon nanoflakes. As should be appreciated, when the nano-sized carbon structures are selected, one would need to select the particular grade for the structures. For example, as is known, there are many grades of carbon fibers commercially available. As such, one would select the grade which has or is able to be produced to have a desirable diameter dimension, yet also exhibits low electrical resistivity and high strength properties. In certain embodiments, the fillers have an outer diameter ranging in size from about 70 nanometers to about 500 nanometers.


As further shown, in certain embodiments, the nano-sized non-metallic conductive structures 78 are each coated with a metal coating 82, including but not limited to Ag, Au, Cu, Co, Ni, Pt, Sn, Ta, Ti, Zn, alloys thereof, as well as any combination thereof. As such, the nano-sized non-metallic conductive structures 78 can be prevented from clumping so as to be uniformly disbursed in the resin 76 and the conductivity of the fillers can be enhanced. The covering 74 is not in direct electrical contact with the conductors of the conductor assembly of the lead/extension 70. In certain embodiments, the covering 74 can be in contact with the housing of the medical device (e.g., IMD) from which they stem, where the device can act as an additional surface for dissipation of energy received by the covering 74 from electromagnetic radiation.


It should be appreciated that the lead/extension 70 can be either a lead, an extension for a lead, or both. For example, with respect to the IMD 10 of FIG. 1, the leads 16, the lead extensions 14, or both, can be equipped with the covering 74. The above similarly holds true for the leads 38a, 38b and extensions 36a, 36b with respect to the IMD 30 of FIG. 2.


The amount of the discontinuous fillers, or combinations of fillers formed of different materials, to be incorporated into the matrix material can vary depending on the desired properties exhibited by the particular medical device or medical device component. As described above, enough of the discontinuous fillers should be included so that desired properties are at least minimally exhibited by the composite, but not so much of the fillers should be included so as to have a detrimental effect on the properties of the composite. While the particular range may vary depending on the filler and matrix materials being utilized, composites exhibiting advantageous properties can be obtained by incorporating from about 0.005% to about 99% filler material relative of the total final composition weight of the composite. In many embodiments, filler material may be incorporated in an amount of from about 0.01% up to about 40% or 50% by weight of the composite. In a typical embodiment, the filler material can be incorporated in an amount of from about 0.1% to about 20% of the composite, for example, from about 1% to about 10% by weight of the composite.


Each of FIGS. 9-12 shows a cross-sectional view of an implantable lead having a plurality of shielding coverings in accordance with certain embodiments of the invention. Each of the implantable leads/extensions of FIGS. 9-12 includes the insulating layer 72 and the covering 74 shown and described in FIG. 8. Further, each of the leads/extensions 70 of FIGS. 9-12 includes one or more additional layers located proximate or adjacent to the covering 74. While each of the insulating layers 72, the coverings 74, and the one or more additional layers are shown to have similar thicknesses in FIGS. 9-12, such is done to merely show the proper position of the layers with respect to one another. As such, the invention should not be limited by the thickness of the layers represented in FIGS. 9-12.



FIG. 9 illustrates lead/extension 90. In certain embodiments, as shown, a coating 92 lies external to the covering 74. In certain embodiments, the coating 92 comprises one or more metals. As such, the coating 92 is adapted to enhance the shielding effect of the lead/extension 90. In certain embodiments, the one or more metals can include Ag, Au, Cu, Co, Ni, Pt, Sn, Ta, Ti, Zn, alloys thereof, as well as any combination thereof; however, the invention should not be limited to such. Instead, the one or more metals can include any metal or combination of metals which can be used in conjunction with the covering 74 to enhance the shielding effect of the lead/extension 90. In certain embodiments, if the coating 92 is to be kept thin, the coating 92 may be applied to the covering 74 via sputtering, physical vapor deposition, chemical vapor deposition, auto-catalytic electroless deposition, electrolytic deposition, or by any other suitable application method.



FIG. 10 shows lead/extension 100. In certain embodiments, as shown, additional layers 102 lie internal to the covering 74; however, the invention should not so limited, as the additional layers 102, while not shown as such, can alternatively lie external to the covering 74 just as well. In certain embodiments, the layers 102 are formed of a braided metal sheath or mesh 104 with an optional outer insulation layer 106. As such, the additional layers 102 are adapted to enhance the shielding effect of the lead/extension 100. In addition, the layers 102 are useful for increasing the torsional stiffness of the conductor assembly, thereby aiding the insertion of the lead/extension 100 within the patient. In certain embodiments, the braided metal sheath or mesh 104 can be formed of Ni, Ta, Ti, or superalloy MP35N; however, the invention should not be limited to such. Instead, the metal sheath or mesh 104 can include any metal or combination of metals or alloys which can be used to enhance the shielding effect of the lead/extension 100. When used, the outer insulation layer 106 can be formed of silicone, a biocompatible polymer such as polyurethane, or any suitable biocompatible, non-conducting material known in the art.



FIG. 11 illustrates lead/extension 110. As can be appreciated, the lead/extension 110 is a combination of lead/extension 90 of FIG. 9 and lead/extension 100 of FIG. 10. As such, the lead/extension 110 has the coating 92 (as described above with respect to FIG. 9) lying external to the covering 74 and the additional layers 102 (as described above with respect to FIG. 10) lying either internal (as shown) or external to the covering 74. As described above, the coating 92 and the additional layers 102 are used in combination to enhance the shielding effect of the lead/extension 110.



FIG. 12 shows lead/extension 120. In certain embodiments, as shown, a further layer 122 lies internal to the covering 74. The layer 122 is formed of a conductive non-metallic material that is in a wrapped or woven form. Such conductive non-metallic materials and embodiments in which the materials are used for medical device lead shielding are described in more detail in the U.S. patent application entitled “Continuous Conductive Materials for Electromagnetic Shielding”, which is filed concurrently herewith and incorporated herein in its entirety. In certain embodiments, the conductive non-metallic material can be carbon. The carbon, in certain embodiments, is formed of one or more of carbon fiber, carbon nanofiber, and carbon nanotube having one or more of single and multiple walls. In certain embodiments, the conductive material has an outer diameter that is preferably no greater than about 20 μm (generally representing minimum diameter of metal wire), and more preferably, no greater than about 12 μm. The conductive material, in certain embodiments, has a higher skin depth than metals. In certain embodiments, the conductive non-metallic material is covered with a metal coating, thereby enhancing the conductivity of the layer 122. In summary, the layer 122 is adapted to enhance the shielding effect of the lead/extension 120. While the layer 122 is shown to be internal to the covering 74, the invention should not be limited to such, as the layer 122 could just as well be switched in position with the covering 74 (so that the further layer 122 lies external to the covering 74) so as to still enhance the shielding effect of the lead/extension 120.


In certain embodiments, the lead/extension 120 of FIG. 12 may further contain one or more of the coating 92 of FIG. 9 and the additional layers 102 of FIG. 10 to further enhance the shielding effect of the lead/extension 120. If the coating 92 is included on the lead/extension 120, in certain embodiments, the coating 92 can lie external to one or more of the continuous conductive fiber layer 122 and the covering 74. If the additional layers 102 are included on the lead/extension 120, in certain embodiments, the additional layers 102 can lie internal or external to the continuous conductive fiber layer 122, and internal or external to the covering 74.


It will be appreciated the embodiments of the present invention can take many forms. The true essence and spirit of these embodiments of the invention are defined in the appended claims, and it is not intended the embodiment of the invention presented herein should limit the scope thereof.

Claims
  • 1. A medical electrical lead, comprising: a conductor assembly having one or more conductors covered by an insulating layer; anda shield covering adjacent or proximate to at least a portion of the insulating layer to shield the conductors from one or more electromagnetic fields, the shield covering comprising a polymer-matrix composite, the polymer-matrix composite including a polymeric resin having discontinuous conductive fillers provided therein, the discontinuous conductive fillers comprising nano-sized non-metallic conductive structures, the discontinuous conductive fillers being gradiently distributed radially at least within a continuous portion of the polymer-matrix composite with a greater concentration at the surface of the shield covering and being uniformly distributed circumferentially and longitudinally at the surface of the polymer-matrix, the shield covering being circumferentially and longitudinally continuous over an entire length of the shield covering.
  • 2. The medical electrical lead of claim 1, wherein the nano-sized non-metallic conductive structures are formed of carbon.
  • 3. The medical electrical lead of claim 2, wherein the nano-sized non-metallic conductive structures comprise one or more of carbon nanofibers, carbon filaments, carbon nanotubes, and carbon nanoflakes.
  • 4. The medical electrical lead of claim 3, wherein the nano-sized non-metallic conductive structures comprise carbon nanofibers.
  • 5. The medical electrical lead of claim 4, wherein the carbon nanofibers have an outer diameter ranging in size from about 70 nanometers to about 500 nanometers.
  • 6. The medical electrical lead of claim 1, further comprising a further layer formed of a conductive non-metallic material being in a wrapped or woven form, the further layer positioned either internal or external to the shield covering, the further layer and the shield covering providing an enhanced shielding effect for the one or more conductors.
  • 7. The medical electrical lead of claim 6, wherein the conductive non-metallic material has a higher skin depth than metals.
  • 8. The medical electrical lead of claim 6, wherein the conductive non-metallic material has an outer diameter that is no greater than about 20 μm.
  • 9. The medical electrical lead of claim 6, wherein the conductive non-metallic material comprises carbon.
  • 10. The medical electrical lead of claim 1, wherein the nano-sized non-metallic conductive structures each has an outer metal coating.
  • 11. The medical electrical lead of claim 10, wherein the outer metal coating prevents a natural tendency of the structures from clumping together.
  • 12. The medical electrical lead of claim 10, wherein the outer metal coating enhances electromagnetic radiation shielding effectiveness of the nano-sized non-metallic conductive structures, the outer metal coating having a thickness of no greater than about 1 μm.
  • 13. The medical electrical lead of claim 1, further comprising a coating formed of one or more metals, the coating positioned external to the shield covering, the coating and the shield covering providing an enhanced shielding effect for the one or more conductors.
  • 14. The medical electrical lead of claim 1, further comprising one or more additional layers positioned internal to the shield covering, one of the additional layers comprising a braided metal sheath or mesh, the one additional layer and the shield covering providing an enhanced shielding effect for the one or more conductors.
  • 15. The lead of claim 1, wherein the lead is coupled to a medical device.
  • 16. An implantable medical lead for alleviating the adverse effects of various health ailments of a patient comprising: a lead body having a proximal end and a distal end, the distal end;one or more electrodes or electrical contacts for sensing and/or therapy delivery on the lead body;a conductor assembly having one or more conductors covered by an insulating layer of the lead body;a shield covering coupled to the lead body and comprising a polymer-matrix composite, the polymer-matrix composite including a polymeric resin having discontinuous conductive fillers provided therein, the discontinuous conductive fillers comprising nano-sized non-metallic conductive structures, the discontinuous conductive fillers being gradiently distributed radially at least within a continuous portion of the polymer-matrix composite with a greater concentration at the surface of the shield covering and being uniformly distributed circumferentially and longitudinally at the surface of the polymer-matrix, the shield covering being circumferentially and longitudinally continuous over an entire length of the shield covering.
  • 17. The lead of claim 16, wherein the lead is coupled to a medical device.
  • 18. An implantable medical lead for alleviating the adverse effects of various health ailments of a patient comprising: a lead body having a proximal end and a distal end, the distal end;one or more electrodes or electrical contacts for sensing and/or therapy delivery on the lead body;a conductor assembly having one or more conductors covered by an insulating layer of the lead body;a shield covering adjacent in a radial direction or proximate in the radial direction to at least a portion of the insulating layer to shield the conductors from one or more electromagnetic fields, the shield covering comprising a polymer-matrix composite, the polymer-matrix composite including a polymeric resin having discontinuous conductive fillers provided therein, the discontinuous conductive fillers comprising nano-sized non-metallic conductive structures, the discontinuous conductive fillers being gradiently distributed radially at least within a continuous portion of the polymer-matrix composite with a greater concentration at the surface of the shield covering and being uniformly distributed circumferentially and longitudinally at the surface of the polymer-matrix, the shield covering being circumferentially and longitudinally continuous over an entire length of the shield covering.
  • 19. The lead of claim 18, wherein the lead is coupled to a medical device.
US Referenced Citations (471)
Number Name Date Kind
2433480 Rendich Dec 1947 A
2487038 Jasper Nov 1949 A
3788329 Friedman Jan 1974 A
3842485 Bemert Oct 1974 A
3915174 Preston Oct 1975 A
4033355 Amundson Jul 1977 A
4038990 Thompson Aug 1977 A
4214804 Little Jul 1980 A
4220813 Kyle Sep 1980 A
4280507 Rosenberg Jul 1981 A
4320763 Money Mar 1982 A
4350169 Dutcher Sep 1982 A
4383225 Mayer May 1983 A
4403824 Scott Sep 1983 A
4441498 Nordling Apr 1984 A
4628942 Sweeney et al. Dec 1986 A
4683895 Pohndorf Aug 1987 A
4711027 Harris Dec 1987 A
4726379 Altman et al. Feb 1988 A
4852585 Heath Aug 1989 A
4906241 Noddin Mar 1990 A
4920980 Jackowski May 1990 A
4922607 Doan et al. May 1990 A
4934380 De Toledo Jun 1990 A
4947866 Lessar et al. Aug 1990 A
4951672 Buchwald et al. Aug 1990 A
4991583 Silvian Feb 1991 A
5003992 Holleman Apr 1991 A
5005587 Scott Apr 1991 A
5012045 Sato Apr 1991 A
5018523 Bach, Jr. et al. May 1991 A
5020544 Dahl et al. Jun 1991 A
5020545 Soukup Jun 1991 A
5036862 Pohndorf Aug 1991 A
5040544 Lessar et al. Aug 1991 A
5063932 Dahl et al. Nov 1991 A
5197468 Proctor et al. Mar 1993 A
5213111 Cook et al. May 1993 A
5217010 Tsitlik et al. Jun 1993 A
5231078 Riebman et al. Jul 1993 A
5243996 Hall Sep 1993 A
5246438 Langberg Sep 1993 A
5260128 Ishii et al. Nov 1993 A
5265608 Lee et al. Nov 1993 A
5265623 Kroll et al. Nov 1993 A
5271417 Swanson et al. Dec 1993 A
5308664 House et al. May 1994 A
5314459 Swanson et al. May 1994 A
5323776 Blakely et al. Jun 1994 A
5335657 Terry, Jr. et al. Aug 1994 A
5349133 Rogers Sep 1994 A
5360441 Otten Nov 1994 A
5366496 Dahl et al. Nov 1994 A
5370644 Langberg Dec 1994 A
5374286 Morris Dec 1994 A
5374778 Hashimoto et al. Dec 1994 A
5417719 Hull et al. May 1995 A
5456705 Morris Oct 1995 A
5458629 Baudino et al. Oct 1995 A
5458631 Xavier Oct 1995 A
5466252 Soukup et al. Nov 1995 A
5473812 Morris et al. Dec 1995 A
5476496 Strandberg et al. Dec 1995 A
5483022 Mar Jan 1996 A
5485667 Kleshinski Jan 1996 A
5500013 Buscemi et al. Mar 1996 A
5504274 McCabe et al. Apr 1996 A
5514172 Mueller May 1996 A
5515848 Corbett, III et al. May 1996 A
5523534 Meister et al. Jun 1996 A
5523578 Herskovic Jun 1996 A
5527348 Winkler Jun 1996 A
5534018 Wahlstrand Jul 1996 A
5552565 Cartier et al. Sep 1996 A
5571157 McConnell Nov 1996 A
5572594 DeVoe et al. Nov 1996 A
5591218 Jacobson Jan 1997 A
5594304 Graber Jan 1997 A
5606981 Tartacower et al. Mar 1997 A
5609622 Soukup et al. Mar 1997 A
5628780 Helland et al. May 1997 A
5629622 Scampini May 1997 A
5643254 Scheldrup et al. Jul 1997 A
5649965 Pons et al. Jul 1997 A
5662697 Li et al. Sep 1997 A
5676659 McGurk Oct 1997 A
5676694 Boser et al. Oct 1997 A
5683435 Truex et al. Nov 1997 A
5683444 Huntley et al. Nov 1997 A
5697909 Eggers et al. Dec 1997 A
5697958 Paul et al. Dec 1997 A
5702437 Baudino Dec 1997 A
5706826 Schwager Jan 1998 A
5722998 Prutchi et al. Mar 1998 A
5727552 Ryan Mar 1998 A
5751539 Stevenson et al. May 1998 A
5766232 Grevious et al. Jun 1998 A
5782241 Felblinger et al. Jul 1998 A
5795341 Samson Aug 1998 A
5807258 Cimochowski et al. Sep 1998 A
5814076 Brownlee Sep 1998 A
5827997 Chung et al. Oct 1998 A
5830136 Delonzor et al. Nov 1998 A
5842966 Markoll Dec 1998 A
5842986 Avrin et al. Dec 1998 A
5851226 Skubitz et al. Dec 1998 A
5897584 Herman Apr 1999 A
5905627 Brendel et al. May 1999 A
5927345 Samson Jul 1999 A
5931861 Werner et al. Aug 1999 A
5954760 Jarl Sep 1999 A
5964705 Truwit et al. Oct 1999 A
5968087 Hess Oct 1999 A
5970429 Martin Oct 1999 A
5942966 Markoll Dec 1999 A
6004269 Crowley et al. Dec 1999 A
6016447 Juran et al. Jan 2000 A
6024703 Zanelli et al. Feb 2000 A
6032063 Hoar et al. Feb 2000 A
6033408 Gage et al. Mar 2000 A
6055457 Bonner Apr 2000 A
6101417 Vogel et al. Aug 2000 A
6103037 Wilson Aug 2000 A
6108582 Fischer, Sr. Aug 2000 A
6132390 Cookston et al. Oct 2000 A
6141593 Patag Oct 2000 A
6143013 Samson et al. Nov 2000 A
6152746 Brown Nov 2000 A
6156029 Mueller Dec 2000 A
6195267 MacDonald et al. Feb 2001 B1
6198807 DeSena Mar 2001 B1
6198972 Hartlaub et al. Mar 2001 B1
6209764 Hartlaub et al. Apr 2001 B1
6240322 Peterfeso May 2001 B1
6258071 Brookes Jul 2001 B1
6265466 Glatkowski Jul 2001 B1
6269148 Jessop et al. Jul 2001 B1
6284971 Atalar et al. Sep 2001 B1
6302740 Holmstrom Oct 2001 B1
6348070 Teissl et al. Feb 2002 B1
6424234 Stevenson Jul 2002 B1
6471699 Fleischman et al. Oct 2002 B1
6488704 Connelly et al. Dec 2002 B1
6494916 Babalola et al. Dec 2002 B1
6501991 Honeck et al. Dec 2002 B1
6503648 Wang Jan 2003 B1
6506972 Wang Jan 2003 B1
6529774 Greene Mar 2003 B1
6538191 MacDonald Mar 2003 B1
6583361 Clouet Jun 2003 B2
6606521 Paspa et al. Aug 2003 B2
6640137 MacDonald Oct 2003 B2
6648690 Saito et al. Nov 2003 B2
6660116 Wolf et al. Dec 2003 B2
6671544 Baudino Dec 2003 B2
6671554 Gibson et al. Dec 2003 B2
6673999 Wang et al. Jan 2004 B1
6675033 Lardo et al. Jan 2004 B1
6689835 Amarasekera et al. Feb 2004 B2
6695761 Oschman et al. Feb 2004 B2
6708051 Durousseau Mar 2004 B1
6711440 Deal et al. Mar 2004 B2
6712844 Pacetti et al. Mar 2004 B2
6713671 Wang et al. Mar 2004 B1
6718203 Weiner et al. Apr 2004 B2
6718207 Connelly Apr 2004 B2
6725092 MacDonald et al. Apr 2004 B2
6735471 Hill et al. May 2004 B2
6741892 Meadows et al. May 2004 B1
6743055 Flynn Jun 2004 B1
6750055 Connelly et al. Jun 2004 B1
6757566 Weiner et al. Jun 2004 B2
6760628 Weiner et al. Jul 2004 B2
6763268 MacDonald et al. Jul 2004 B2
6765144 Wang et al. Jul 2004 B1
6768053 Wang et al. Jul 2004 B1
6778856 Connelly et al. Aug 2004 B2
6792316 Sass Sep 2004 B2
6793642 Connelly et al. Sep 2004 B2
6795730 Connelly et al. Sep 2004 B2
6795736 Connelly et al. Sep 2004 B2
6799067 Pacetti Sep 2004 B2
6799069 Weiner et al. Sep 2004 B2
6815609 Wang et al. Nov 2004 B1
6819954 Connelly Nov 2004 B2
6819958 Weiner et al. Nov 2004 B2
6844492 Wang et al. Jan 2005 B1
6845259 Pacetti et al. Jan 2005 B2
6845267 Harrison et al. Jan 2005 B2
6846985 Wang et al. Jan 2005 B2
6850805 Connelly et al. Feb 2005 B2
6852091 Edwards et al. Feb 2005 B2
6863653 Zanelli et al. Mar 2005 B1
6864418 Wang et al. Mar 2005 B2
6869683 Sakurai et al. Mar 2005 B2
6871091 Wilkinson et al. Mar 2005 B2
6872882 Fritz Mar 2005 B2
6875180 Weiner et al. Apr 2005 B2
6879861 Benz et al. Apr 2005 B2
6882519 Uzawa et al. Apr 2005 B2
6895280 Meadows et al. May 2005 B2
6901287 Davis et al. May 2005 B2
6901290 Foster et al. May 2005 B2
6906256 Wang Jun 2005 B1
6920361 Williams Jul 2005 B2
6922590 Whitehurst Jul 2005 B1
6925328 Foster et al. Aug 2005 B2
6930242 Helfer Aug 2005 B1
6937906 Terry et al. Aug 2005 B2
6944489 Zeiljemaker et al. Sep 2005 B2
6949929 Gray et al. Sep 2005 B2
6954674 Connelly Oct 2005 B2
6968235 Belden et al. Nov 2005 B2
6968236 Hagele Nov 2005 B2
6971391 Wang et al. Dec 2005 B1
6980865 Wang et al. Dec 2005 B1
6982378 Dickson Jan 2006 B2
6985775 Reinke et al. Jan 2006 B2
6993387 Connelly et al. Jan 2006 B2
6999818 Stevenson et al. Feb 2006 B2
6999821 Jenney et al. Feb 2006 B2
7001369 Griffin et al. Feb 2006 B2
7013174 Connelly et al. Mar 2006 B2
7013180 Villaseca et al. Mar 2006 B2
7015392 Dickenson Mar 2006 B1
7015393 Weiner Mar 2006 B2
7047084 Erickson May 2006 B2
7050855 Zeijlemaker et al. May 2006 B2
7058192 Muller et al. Jun 2006 B2
7076283 Cho et al. Jul 2006 B2
7076302 Scheiner Jul 2006 B2
7082328 Funke Jul 2006 B2
7082337 Sommer et al. Jul 2006 B2
7103413 Swanson Sep 2006 B2
7113827 Silvestri Sep 2006 B2
7115134 Chambers Oct 2006 B2
7118693 Glatkowski et al. Oct 2006 B2
7123013 Gray Oct 2006 B2
7125409 Truckai et al. Oct 2006 B2
7162302 Wang et al. Jan 2007 B2
7174219 Wahlstrand et al. Feb 2007 B2
7187980 Osypka et al. Mar 2007 B2
7233825 Jorgenson et al. Jun 2007 B2
7257449 Bodner Aug 2007 B2
7282260 LeGrande et al. Oct 2007 B2
7286871 Cohen Oct 2007 B2
7286882 Cole Oct 2007 B2
7292894 Belden Nov 2007 B2
7294785 Uutela et al. Nov 2007 B2
7319901 Dublin Jan 2008 B2
7363090 Halperin Apr 2008 B2
7389148 Morgan Jun 2008 B1
7540865 Griffin et al. Jun 2009 B2
7548788 Chinn et al. Jun 2009 B2
7591831 Parsonage et al. Sep 2009 B2
7674972 Gladd et al. Mar 2010 B2
7711436 Stone May 2010 B2
7729777 Gray et al. Jun 2010 B2
7738942 Weiner Jun 2010 B2
7813811 Wingeier et al. Oct 2010 B2
7819826 Diederich et al. Oct 2010 B2
7822484 Zhao et al. Oct 2010 B1
7828833 Haverkost Nov 2010 B2
7844343 Wahlstrand Nov 2010 B2
7844344 Wahlstrand Nov 2010 B2
7853332 Olsen Dec 2010 B2
7877150 Hoegh et al. Jan 2011 B2
7904178 Williams Mar 2011 B2
7917213 Bulkes Mar 2011 B2
7933652 Phillips Apr 2011 B2
8007440 Magnin et al. Aug 2011 B2
8027736 Wahlstrand Sep 2011 B2
8036756 Swoyer et al. Oct 2011 B2
8048060 Griffin et al. Nov 2011 B2
8055351 Atalar et al. Nov 2011 B2
8106657 Sakellariou et al. Jan 2012 B2
8170691 Eckerdal May 2012 B2
8202259 Evans et al. Jun 2012 B2
8246643 Nita Aug 2012 B2
8275464 Li et al. Sep 2012 B2
8280526 Wahlstrand Oct 2012 B2
8483842 Alexander et al. Jul 2013 B2
8620455 Alexander et al. Dec 2013 B2
8676340 Wahlstrand Mar 2014 B2
8744598 Alexander et al. Jun 2014 B2
8788061 Mehdizadeth Jul 2014 B2
8805534 Olsen Aug 2014 B2
8903504 Hegland Dec 2014 B2
9002474 Olsen Apr 2015 B2
9037263 Marshall May 2015 B2
9044593 Li Jun 2015 B2
20010044646 Marshall et al. Nov 2001 A1
20020032468 Hill Mar 2002 A1
20020038135 Connelly et al. Mar 2002 A1
20020058978 Sass May 2002 A1
20020183438 Amarasekera et al. May 2002 A1
20020082673 Benz et al. Jun 2002 A1
20020106918 Saito et al. Aug 2002 A1
20020111659 Davis et al. Aug 2002 A1
20020111663 Dahl et al. Aug 2002 A1
20020116028 Greatbatch et al. Aug 2002 A1
20020116029 Miller et al. Aug 2002 A1
20020116033 Greatbatch et al. Aug 2002 A1
20020116034 Miller et al. Aug 2002 A1
20020128689 Connelly et al. Sep 2002 A1
20020128691 Connelly Sep 2002 A1
20020133086 Connelly et al. Sep 2002 A1
20020133199 MacDonald et al. Sep 2002 A1
20020133200 Weiner et al. Sep 2002 A1
20020133201 Connelly et al. Sep 2002 A1
20020133202 Connelly et al. Sep 2002 A1
20020133208 Connelly Sep 2002 A1
20020133211 Weiner et al. Sep 2002 A1
20020133216 Connelly et al. Sep 2002 A1
20020138102 Weiner et al. Sep 2002 A1
20020138107 Weiner et al. Sep 2002 A1
20020138108 Weiner et al. Sep 2002 A1
20020138110 Connelly et al. Sep 2002 A1
20020138112 Connelly et al. Sep 2002 A1
20020143377 Wessman et al. Oct 2002 A1
20020183740 Edwards et al. Dec 2002 A1
20020183822 Bodner Dec 2002 A1
20020188345 Pacetti Dec 2002 A1
20030009207 Paspa et al. Jan 2003 A1
20030014080 Baudino Jan 2003 A1
20030036776 Foster et al. Feb 2003 A1
20030044623 Sakurai et al. Mar 2003 A1
20030045920 Belden et al. Mar 2003 A1
20030060732 Jacobsen et al. Mar 2003 A1
20030083570 Cho et al. May 2003 A1
20030083723 Wilkinson et al. May 2003 A1
20030083726 Zeijlemaker et al. May 2003 A1
20030093107 Parsonage et al. May 2003 A1
20030109901 Greatbatch Jun 2003 A1
20030117787 Nakauchi Jun 2003 A1
20030120148 Pacetti Jun 2003 A1
20030120197 Kaneko et al. Jun 2003 A1
20030135114 Pacetti et al. Jul 2003 A1
20030139794 Jenney et al. Jul 2003 A1
20030139806 Haverkost et al. Jul 2003 A1
20030140931 Zeijlemaker Jul 2003 A1
20030144704 Terry Jul 2003 A1
20030144705 Funke Jul 2003 A1
20030144716 Reinke et al. Jul 2003 A1
20030144717 Hegele Jul 2003 A1
20030144718 Zeijlemaker Jul 2003 A1
20030144719 Zeijlemaker Jul 2003 A1
20030144720 Villaseca et al. Jul 2003 A1
20030144721 Villaseca et al. Jul 2003 A1
20030167052 Lee et al. Sep 2003 A1
20030204217 Greatbatch Oct 2003 A1
20030225331 Diederich et al. Dec 2003 A1
20040020674 McFadden et al. Feb 2004 A1
20040024442 Sowinski et al. Feb 2004 A1
20040028859 LeGrande et al. Feb 2004 A1
20040068307 Goble Apr 2004 A1
20040071949 Glatkowski et al. Apr 2004 A1
20040088012 Kroll et al. May 2004 A1
20040106958 Mathis et al. Jun 2004 A1
20040162600 Williams Aug 2004 A1
20040167443 Shireman et al. Aug 2004 A1
20040173368 Dickson Sep 2004 A1
20040199069 Connelly Oct 2004 A1
20040220549 Dittman et al. Nov 2004 A1
20040249428 Wang et al. Dec 2004 A1
20040251042 Weiner et al. Dec 2004 A1
20040263172 Gray et al. Dec 2004 A1
20040263173 Gray Dec 2004 A1
20040263174 Gray et al. Dec 2004 A1
20040267328 Duffin Dec 2004 A1
20050065587 Gryzwa Mar 2005 A1
20050070972 Wahlstrand Mar 2005 A1
20050080471 Chitre et al. Apr 2005 A1
20050113876 Weiner May 2005 A1
20050115624 Walak Jun 2005 A1
20050137664 Sommer et al. Jun 2005 A1
20050145307 Shireman et al. Jul 2005 A1
20050159661 Connelly et al. Jul 2005 A1
20050182471 Wang Aug 2005 A1
20050222642 Przybyszewski Oct 2005 A1
20050222647 Wahlstrand Oct 2005 A1
20050222656 Wahlstrand Oct 2005 A1
20050222657 Wahlstrand Oct 2005 A1
20050222658 Hoegh et al. Oct 2005 A1
20050222659 Olsen Oct 2005 A1
20060030918 Chinn et al. Feb 2006 A1
20060036306 Heist et al. Feb 2006 A1
20060079926 Desai et al. Apr 2006 A1
20060089680 Bruchmann et al. Apr 2006 A1
20060095078 Tronnes May 2006 A1
20060135962 Kick et al. Jun 2006 A1
20060155270 Hancock Jul 2006 A1
20060167522 Malinowski Jul 2006 A1
20060167527 Malinowski Jul 2006 A1
20060200218 Wahlstrand Sep 2006 A1
20060224207 Dublin Oct 2006 A1
20060247747 Olsen Nov 2006 A1
20060247748 Wahlstrand Nov 2006 A1
20070021811 D'Aquanni et al. Jan 2007 A1
20070106332 Denker May 2007 A1
20070123805 Shireman et al. May 2007 A1
20070129779 Ayre Jun 2007 A1
20070168008 Olsen Jul 2007 A1
20070185556 Williams Aug 2007 A1
20070208383 Williams Sep 2007 A1
20070293924 Belden et al. Dec 2007 A1
20080033497 Bulkes Feb 2008 A1
20080039709 Karmarkar Feb 2008 A1
20080058715 Houser et al. Mar 2008 A1
20080154326 Clyne Jun 2008 A1
20080183263 Alexander Jul 2008 A1
20080195186 Li Aug 2008 A1
20080195187 Li Aug 2008 A1
20080215008 Nance et al. Sep 2008 A1
20080242944 Sharma Oct 2008 A1
20080243081 Nance et al. Oct 2008 A1
20080243218 Bottomley Oct 2008 A1
20080262582 Alexander Oct 2008 A1
20080262584 Bottomley Oct 2008 A1
20080269863 Alexander Oct 2008 A1
20080287804 Nita Nov 2008 A1
20090204192 Carlton Aug 2009 A1
20090221970 Spinoza Sep 2009 A1
20090228074 Edgell et al. Sep 2009 A1
20090234402 Marshall Sep 2009 A1
20090240235 Murata Sep 2009 A1
20090259272 Reddy Oct 2009 A1
20090270956 Vase Oct 2009 A1
20090287189 Suwito Nov 2009 A1
20100069743 Sheetz et al. Mar 2010 A1
20100100164 Johnson et al. Apr 2010 A1
20100137957 Eckerdal Jun 2010 A1
20100145426 Stone Jun 2010 A1
20100198327 Helland Aug 2010 A1
20100256528 Lippert et al. Oct 2010 A1
20100256604 Lippert et al. Oct 2010 A1
20100268310 Bonde et al. Oct 2010 A1
20100331938 Sommer Dec 2010 A1
20110015713 Min Jan 2011 A1
20110034983 Min Feb 2011 A1
20110071599 Olsen Mar 2011 A1
20110071604 Wahlstrand Mar 2011 A1
20110071605 Wahlstrand Mar 2011 A1
20110112615 Hoegh et al. May 2011 A1
20110160818 Struve Jun 2011 A1
20110230943 Johnson et al. Sep 2011 A1
20110251487 Magnin et al. Oct 2011 A1
20110319905 Palme et al. Dec 2011 A1
20120010689 Wahlstrand Jan 2012 A1
20120035616 Olsen Feb 2012 A1
20120035694 Olsen Feb 2012 A1
20120035695 Olsen et al. Feb 2012 A1
20120035696 Kern Feb 2012 A1
20120035697 Stone Feb 2012 A1
20120035951 Goetz Feb 2012 A1
20120041528 Mehdizadeh et al. Feb 2012 A1
20120041529 Olsen Feb 2012 A1
20120046722 Olsen Feb 2012 A1
20120635696 Kern Feb 2012
20120053664 Hegland Mar 2012 A1
20120059467 Drew Mar 2012 A1
20120130461 Olsen May 2012 A1
20120330383 Wahlstrand Dec 2012 A1
20130296991 Alexander et al. Nov 2013 A1
20140107746 Alexander et al. Apr 2014 A1
20140200643 Wahlstrand Jul 2014 A1
20140288626 Alexander et al. Sep 2014 A1
20140345132 Mehdizadeh et al. Nov 2014 A1
20140350654 Olsen et al. Nov 2014 A1
20150082618 Hegland Mar 2015 A1
20150270792 Alford Jun 2015 A1
Foreign Referenced Citations (82)
Number Date Country
0617978 Oct 1994 EP
0624383 Nov 1994 EP
0713714 May 1996 EP
0760196 Mar 1997 EP
0920239 Jun 1999 EP
1273922 Jan 2003 EP
1424095 Jun 2004 EP
1466576 Oct 2004 EP
1625875 Feb 2006 EP
1632265 Mar 2006 EP
1935449 Jun 2008 EP
2429154 Feb 2007 GB
07255863 Oct 1995 JP
11-086641 Mar 1999 JP
11086641 Mar 1999 JP
WO95032673 Dec 1995 WO
WO96016694 Jun 1996 WO
WO96028951 Sep 1996 WO
WO97041923 Nov 1997 WO
WO98048896 Nov 1998 WO
WO99010035 Mar 1999 WO
WO99019020 Apr 1999 WO
WO99060370 Nov 1999 WO
WO00027279 May 2000 WO
WO01080940 Nov 2001 WO
WO02000292 Jan 2002 WO
WO02083236 Oct 2002 WO
WO03037429 May 2003 WO
WO03061755 Jul 2003 WO
WO03063946 Aug 2003 WO
WO03063948 Aug 2003 WO
WO03063952 Aug 2003 WO
WO03063953 Aug 2003 WO
WO03063954 Aug 2003 WO
WO03063955 Aug 2003 WO
WO03063956 Aug 2003 WO
WO03063957 Aug 2003 WO
WO03075797 Sep 2003 WO
WO03092326 Nov 2003 WO
WO03095022 Nov 2003 WO
WO04012809 Feb 2004 WO
WO04052448 Jun 2004 WO
WO04073040 Aug 2004 WO
WO05030322 Apr 2005 WO
WO05032654 Apr 2005 WO
WO05102444 Nov 2005 WO
WO05102445 Nov 2005 WO
WO05102446 Nov 2005 WO
WO05102447 Nov 2005 WO
WO06031317 Mar 2006 WO
WO06093685 Sep 2006 WO
WO06093686 Sep 2006 WO
WO06118640 Nov 2006 WO
WO06118641 Nov 2006 WO
WO07047966 Apr 2007 WO
WO07124273 Nov 2007 WO
WO07126657 Nov 2007 WO
WO07149757 Dec 2007 WO
WO08088568 Jul 2008 WO
WO08100839 Aug 2008 WO
WO08100840 Aug 2008 WO
WO08111986 Sep 2008 WO
WO08130409 Oct 2008 WO
WO08134196 Nov 2008 WO
WO08140376 Nov 2008 WO
WO09011440 Sep 2009 WO
WO09134901 Nov 2009 WO
WO10062988 Jun 2010 WO
WO10126871 Nov 2010 WO
WO10126877 Nov 2010 WO
WO10126884 Nov 2010 WO
WO10126887 Nov 2010 WO
WO10126935 Nov 2010 WO
WO10126939 Nov 2010 WO
WO10126943 Nov 2010 WO
WO10126946 Nov 2010 WO
WO10126949 Nov 2010 WO
WO10126975 Nov 2010 WO
WO10135440 Nov 2010 WO
WO11019416 Feb 2011 WO
WO12103419 Aug 2012 WO
WO13158189 Oct 2013 WO
Non-Patent Literature Citations (33)
Entry
PCT/US2004/042081: Search Report and Written Opinion.
PCT/US2005/000322: Search Report and Written Opinion.
PCT/US2008/053540: Search Report and Written Opinion.
PCT/US2008/053541: Search Report and Written Opinion.
PCT/US2008/059358: Search Report and Written Opinion.
PCT/US2009/036461: Search Report and Written Opinion.
PCT/US2010/032516: Search Report and Written Opinion.
PCT/US2010/032526: Search Report and Written Opinion.
PCT/US2010/032543: Search Report and Written Opinion.
PCT/US2010/032560: Search Report and Written Opinion.
PCT/US2010/032567: Search Report and Written Opinion.
PCT/US2010/032666: Search Report and Written Opinion.
PCT/US2010/032671: Search Report and Written Opinion.
PCT/US2010/032675: Search Report and Written Opinion.
PCT/US2010/032682: Search Report and Written Opinion.
PCT/US2010/032719: Search Report and Written Opinion.
PCT/US2013/023637: Search Report and Written Opinion.
Baker et al., “Evaluation of Specific Absorption Rates as a Dosimeter of MRI-Related Implant Heating”, Journal of Magnetic Resonance Imaging 20:315-320 (2004).
Baker, K., et al., “Neurostimulation Systems: Assessment of Magnetic Field Interactions Associated with 1.5 and 3-Tesla MR Systems”, J. Magn. Reson. Imaging, Jan. 2005, 21(1);72-7.
Chung, D.D.L., “Carbon Fiber Composites”, 1994, chapter 1, p. 8, table 1.2, Elsevier, ISBN: 978-0-7506-9169-7.
Chung, D.D.L., Comparison of Submicron-Diameter Carbon Filaments and Conventional Carbon Fibers as Fillers in Composite Materials, Carbon 39 (2001) pp. 1119-1125, Elsevier Science Ltd.
Chung, D.D.L., Electromagnetic Interference Shielding Effectiveness of Carbon Materials, Carbon 29 (2001) pp. 279-285, Elsevier Science Ltd.
Engdahl, Tomi, “Ground Loop Basics.” Web Jan. 4, 2009, ePanorama.net www.epanorama.net/documents/groundloop/basics.html U.S. Appl. No. 11/739,787.
Finelli, D., et al., “MRI Imaging-Related Heating of Deep Brain Stimulation Electrodes: In Vitro Study”, AJNR Am. J. Neuroadiol 23:1, Nov./Dec. 2002.
Jou, W.S. “A Novel Structure of Woven Continuous-Carbon Fiber Composites with High Electromagnetic Shielding”, Journal of Electronic Materials, vol. 33, No. 3, Mar. 1, 2004, pp. 162-170(9), Minerals, Metals and Materials Society, http://findarticles.com/p/articles/mi_qu3776/is_200403/ai_n9405_582/print.
Kolin, et al., “An Electromagnetic Catheter Flow Meter for Determination of Blood Flow in Major Arteries,” Department of Biophysics, Physiology, and Radiology, University of California School of Medicine (Los Angeles) Jan. 19, 1988, Proc. N.A.S. vol. 59, pp. 808-815.
Kolin, et al., “An Electromagnetic Intravascular Blood-Flow Sensor”, Department of Biophysics, University of California School of Medicine (Los Angeles), Mar. 20, 1967, Proc. N.A.S., vol. 57, pp. 1331-1337.
Kolin, et al., “Miniaturization of the Electromagnetic Blood Flow Meter and its Use for the Recording of Circulatory Responses of Conscious Animals to Sensory Stimuli”, Department of Biophysics, University of California at Los Angeles, Aug. 1959, Proc. N.A.S. vol. 45(8), pp. 1312-1321.
Medtronic Activa Product Family and Procedure Solution Brochure, Medtronic, Inc, 2001.
Medtronic Neurostimulation Systems Brochure, Medtronic, Inc., 2002.
Quick et al., “Endourethral MRI”, Magnetic Resonance in Medicine, 45:138-146, 2001.
Rezai, A., et al., “Neurostimulation System Used for Deep Brain Stimulation (DBS): MR Safety Issues and Implications of Failing to Follow Safety Recommendations” Investigative Radiology, May 2004, vol. 39, Issue 5, pp. 300-303.
Rezai, A., et al., “Neurostimulation Systems for Deep Brain Stimulation In Vitro Evaluation of Magnetic Resonance Imaging-Related Healing at 1.5 Tesla”, Journal of Magnetic Reson. Imaging 2002; 15:241-50.
Related Publications (1)
Number Date Country
20150258335 A1 Sep 2015 US
Divisions (1)
Number Date Country
Parent 11674992 Feb 2007 US
Child 14717881 US